ARTICLE | Clinical News
JAK2 MutaSearch regulatory update
November 9, 2009 8:00 AM UTC
Ipsogen received CE Mark approval in the EU for its JAK2 MutaSearch and MutaQuant kits for myoproliferative disorders. The MutaSearch kit is designed to detect the janus kinase-2 (JAK-2) V617F mutati...